Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-ROR1 CAR-T cells BMS-986403

A preparation of autologous T lymphocytes genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) receptor tyrosine kinase-like orphan receptor 1 (ROR1), with potential immunomodulatory and antineoplastic activities. After isolation, transduction, expansion and reintroduction into the patient, the autologous anti-ROR1 CAR-T cells BMS-986403 are directed to, bind to, and induce selective toxicity in tumor cells expressing ROR1. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), is expressed during embryogenesis and in various hematological and solid malignancies. It plays key roles in tumor cell proliferation and survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous ROR1-targeted CAR T cells BMS-986403
Code name:BMS 986403
BMS-986403
BMS986403
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search